QIAGEN acquires Genoox to boost genomics AI

NETHERLANDS – QIAGEN has announced the acquisition of Genoox, a Tel Aviv-based company known for its advanced AI-powered software for clinical genetic testing.

QIAGEN acquired Genoox for US $70 million in cash, with the potential for an additional US $10 million in milestone payments.

The deal is projected to generate about US $5 million in sales in 2025 and have a neutral impact on QIAGEN’s adjusted earnings per share.

This strategic move brings Genoox’s flagship platform, Franklin, into QIAGEN’s Digital Insights portfolio, enhancing the company’s leadership in clinical genomics.

Franklin is a cloud-based platform designed to help laboratories interpret next-generation sequencing (NGS) data, from focused gene panels to full exome and genome sequencing.

The platform delivers real-time, AI-driven insights that support doctors and clinicians in making critical decisions across areas like genetic disease diagnosis, cancer treatment planning, and family health.

Used by more than 4,000 healthcare organizations in over 50 countries, Franklin has supported more than 750,000 clinical interpretations so far.

The addition of Franklin gives QIAGEN’s customers access to an intuitive, scalable solution that simplifies complex genetic data analysis and speeds up diagnosis.

Founded in 2014, Genoox has built a strong reputation for combining cloud technology with artificial intelligence to make genetic data more useful for clinicians and researchers.

Franklin stands out by offering not only AI-based interpretation but also access to a global community of experts, enhancing collaboration and knowledge sharing.

Thierry Bernard, CEO of QIAGEN, said the acquisition brings together powerful, complementary tools that will make clinical labs more efficient. “Franklin’s smart interpretation engine helps labs focus on what matters most—improving patient care,” he noted.

Amir Trabelsi, CEO and Co-founder of Genoox, added that joining QIAGEN is a milestone that will allow the Franklin platform to reach more labs and patients globally. “Together, we can scale precision medicine faster,” he said.

The acquisition also lays the groundwork for deeper integration between QIAGEN’s genomic resources, like the Human Gene Mutation Database (HGMD), the Catalogue of Somatic Mutations in Cancer (COSMIC), the QIAGEN Knowledge Base (QKB), and the Franklin platform.

These additions are expected to boost diagnostic accuracy, reduce turnaround times, and allow labs to handle more cases efficiently.